# The Supplementation Therapy in Autism and Response to Treatment Study

> **NCT06187090** · NA · RECRUITING · sponsor: **University of Udine** · enrollment: 20 (estimated)

## Conditions studied

- Autism
- Autism Spectrum Disorder
- Autism Spectrum Disorder High-Functioning
- Asperger Syndrome
- Depressive Symptoms
- Anxiety State

## Interventions

- **DIETARY_SUPPLEMENT:** Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form

## Key facts

- **NCT ID:** NCT06187090
- **Lead sponsor:** University of Udine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-11
- **Final completion:** 2026-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06187090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06187090, "The Supplementation Therapy in Autism and Response to Treatment Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06187090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*